Mode
Text Size
Log in / Sign up

Jinlida Granule reduces serum creatinine and HbA1c in diabetic kidney disease patients across a meta-analysisJinlida Granule lowers key kidney markers in diabetic kidney disease patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note Jinlida Granule reduces renal markers in DKD, but interpret cautiously due to bias and heterogeneity.

This systematic review and meta-analysis examined the efficacy and safety of Jinlida Granule in patients with diabetic kidney disease. The analysis included data from 1,341 patients. The primary outcomes were not reported, but secondary outcomes included serum creatinine, blood urea nitrogen, urinary albumin excretion rate, HbA1c, lipid profiles, inflammatory markers, and adverse events.

The meta-analysis found significant reductions in serum creatinine with a mean difference of -30.54 µmol/L (95% CI -37.61 to -23.47). Significant reductions were also observed for blood urea nitrogen (MD -0.95 mmol/L, 95% CI -1.29 to -0.60) and urinary albumin excretion rate (MD -27.09 mg/24 h, 95% CI -29.16 to -25.02). HbA1c levels decreased by a mean difference of -0.86% (95% CI -1.23% to -0.49%). Adverse events did not differ significantly between groups (RR 0.86, 95% CI 0.50–1.48).

The authors acknowledge limitations including moderate to high risk of bias and considerable heterogeneity. The certainty note advises that findings should be interpreted cautiously. The practice relevance suggests adjunctive JLD may provide multifaceted clinical benefits for DKD patients, but the evidence is not free from methodological concerns.

Diabetic kidney disease is a serious complication that can lead to kidney failure. A recent analysis looked at a specific herbal treatment called Jinlida Granule to see if it helps people with this condition. The team reviewed data from 1,341 patients who received this treatment alongside their usual care. They compared these results to patients who did not get the treatment. The findings suggest the medicine may offer real benefits for those struggling with diabetes and kidney issues.

The study showed clear improvements in several important health measures. Patients taking Jinlida Granule had lower levels of serum creatinine, which is a waste product the kidneys should filter out. They also had lower blood urea nitrogen, less protein leaking into urine, and better blood sugar control measured by HbA1c. Lipid profiles and inflammatory markers also improved in the treatment group.

Safety was another major concern for the researchers. The data showed that adverse events did not differ significantly between the groups. This means the treatment appeared safe with a comparable safety profile to standard care. However, the researchers noted that the studies included had moderate to high risk of bias and considerable heterogeneity. This means the results should be interpreted cautiously and not overstated as a guaranteed cure.

What this means for you:
Jinlida Granule may help lower kidney stress and blood sugar in diabetic kidney disease, but results need cautious interpretation.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
BackgroundDiabetic kidney disease (DKD), a major microvascular complication of diabetes, represents the leading cause of end-stage renal disease globally. Jinlida Granule (JLD), a multi-botanical Traditional Chinese Medicine preparation, has shown potential in type 2 diabetes management; however, a comprehensive systematic evaluation of its efficacy and safety specifically for DKD is lacking.ObjectiveTo systematically evaluate the efficacy and safety of JLD for DKD through a meta-analysis.MethodsWe conducted a systematic search of Chinese and English databases and clinical trial registries for randomized controlled trials (RCTs) on JLD for DKD from inception to 9 October 2025. Two researchers independently performed literature screening, data extraction, and quality assessment using the Cochrane Risk of Bias (RoB) 2 tool. Meta-analysis was conducted with a random-effects model using STATA 15.0 and Review Manager 5.4. Subgroup and sensitivity analyses were performed.ResultsTwelve RCTs involving 1,341 patients were included. JLD was associated with significant reductions in serum creatinine (MD −30.54 μmol/L, 95% CI −37.61 to −23.47; I2 = 94%), blood urea nitrogen (MD −0.95 mmol/L, 95% CI −1.29 to −0.60; I2 = 79%), urinary albumin excretion rate (MD −27.09 mg/24 h, 95% CI −29.16 to −25.02; I2 = 94%), and HbA1c (MD −0.86%, 95% CI −1.23% to −0.49%; I2 = 83%). Improvements were also observed in lipid profiles and inflammatory markers. Subgroup analyses suggested greater benefit in early-stage DKD and with specific combination regimens. Adverse events did not differ significantly between groups (RR 0.86, 95% CI 0.50–1.48). Substantial heterogeneity was noted.ConclusionCurrent evidence suggests that adjunctive JLD may provide multifaceted clinical benefits for DKD patients, with a comparable safety profile. However, these findings should be interpreted cautiously given the moderate to high risk of bias and considerable heterogeneity. Well-designed, large-scale RCTs are required.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420251178318, identifier [CRD420251178318].
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.